RELATED STUDY

Cannabidiol in inflammatory bowel diseases: a brief overview.

Key Findings:  For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Italy

Year of Pub:  2013


Cannabinoids Studied:  Cannabidiol (CBD)

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype III

Receptors Studied:  PPARs